Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses starting topical finasteride for hair loss, with concerns about high dosages. It suggests starting with a lower concentration, like 0.1% or 0.3%, especially with liposomal versions.

A user is experiencing worsening hair loss despite using 2.5mg Dutasteride, RU58841, and Minoxidil daily for over 8 months. They are concerned that daily nicotine from vaping might be counteracting the treatments.

The user is considering adding RU58841 to liquid minoxidil without propylene glycol (PG) due to an allergy and is asking if this combination is effective and if PG is necessary. They have been using finasteride and minoxidil foam, plan to use RU58841 with liquid minoxidil in the evening, and continue finasteride.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.

A man in his late twenties switched from finasteride to dutasteride for hair loss and is sharing his 3-month progress, noting increased shedding but no side effects. Some responders think the treatment is working.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

The user is currently using finasteride and minoxidil and is considering adding microneedling and either RU58841 or Pyrilutamide for potential hair regrowth. They previously used microneedling, RU58841, and oral minoxidil before their hair transplant.

The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.

The user is considering adding microneedling to their current hair loss regimen, which includes 1mg finasteride daily, 1.25mg oral minoxidil twice daily, and Nizoral once a week. Opinions on microneedling's effectiveness vary, but some suggest it could enhance results.

The user started using topical finasteride three days ago alongside minoxidil and is experiencing testicular pain, which they believe is a nocebo effect. They are anxious about the dosage and seeking advice on whether increasing the application frequency affects the overall dosage.

A user is attempting to recover from severe hair loss using 1.25mg finasteride, 5mg topical minoxidil twice daily, pyrilutamide for a month, RU58841 for two weeks, and weekly microneedling at 1.5mm. They have seen new hair growth after two months and plan to continue the treatment for a year with the hope of regrowing enough hair for a transplant.

A 30-year-old male is experiencing hair loss and is concerned about his receding hairline, seeking advice on his Norwood scale classification. He is apprehensive about using Minoxidil and finasteride as treatments.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

The user is experiencing an allergic reaction to propylene glycol in Kirkland minoxidil and is considering switching to a foam version or a low-PG minoxidil solution. They are also contemplating oral minoxidil but are concerned about its long-term safety.

Higher doses of dutasteride for hair loss are debated, with some users suggesting they are unnecessary and potentially unsafe. The original poster uses a combination of dutasteride, minoxidil, and RU58841 for hair regrowth, despite concerns about high dosages.

A 28-year-old male shares progress using 5mg Minoxidil and 0.5mg Dutasteride for hair growth, encouraging the use of these treatments. Users discuss side effects like increased facial hair and debate the effectiveness of treatments within three months.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

The user has been using topical minoxidil with tretinoin for 9 months without much regrowth and suspects finasteride is responsible for any improvement. They are inquiring about tests to determine response to topical minoxidil and seeking advice on switching to oral minoxidil, including potential side effects and monitoring requirements.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

User experienced good results with topical finasteride, noting reduced DHT and increased testosterone. They plan to revert to a lower dosage after observing slight libido reduction.

A 24-year-old with a high Norwood scale is seeking advice on hair loss treatments and considering a second hair transplant. They currently use topical finasteride and minoxidil, castor oil, and a derma roller, and are advised to switch to oral dutasteride and minoxidil.

The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.

The user experienced significant hair regrowth using 5mg oral Minoxidil and 0.5mg oral Dutasteride daily, with no side effects except increased body and eyebrow hair. They are concerned about progress plateauing but have not experienced shedding.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

The user is increasing their oral minoxidil dosage from 2.5mg to 5mg after using 1mg finasteride and topical minoxidil foam for over three years without desired results. They have also been microneedling and using tretinoin cream, recently increasing the tretinoin dosage to 0.1%.